Clinical trial · Observational
Stage III NSCLC RWE in Chinese Patients
Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients With Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting. This study is a prospective, non-interventional study. It is descriptive in nature and does not attempt to test any specific a priori hypotheses.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
- label
- Cohort 2
- description
- Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
Primary outcomes (1)
- measure
- To observe treatment patterns of unresectable, stage III NSCLC
- timeFrame
- Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months
- description
- Treatment received before disease progress including chemotherapy, targeted therapy, immunotherapy, anti-angiogenesis therapy and radiotherapy
Secondary outcomes (4)
- measure
- To observe the clinical outcome of unresectable, stage III NSCLC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 130 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female aged 18 years or older. * Provision of informed consent prior to any study specific procedures. * Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology). Exclusion Criteria: * Enrolment in studies that prohibit any participation in this observational study. * Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown. * Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.
References
Publications (1)
- DERIVEDXing L, Yu J, Meng X, Zhao R, Yang W, Guo Y, Li J, Fan M, Xiao C, Ren Y, Dong L, Lv D, Zhao L, Lin Y, Zhang X, Chen L, Wang Y, Zhang Y, Zang A, Cheng G, Liu A, Liang N, Lou B, Wang J, Fu X, Shi A, Xu N, Liu J, Xiang ZL. Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study. Target Oncol. 2026 May;21(3):385-398. doi: 10.1007/s11523-026-01217-0. Epub 2026 May 3. PMID 42070217